Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1712-1717

  O'Day, S J ^a   Maio, M ^b   Chiarion Sileni, V ^c   Gajewski, T F ^d   Pehamberger, H ^e   Bondarenko, I N ^f   Queirolo, P ^g   Lundgren, L ^h   Mikhailov, S ⁱ   Roman, L ^j   Verschraegen, C ^k   Humphrey, R ^l   Ibrahim, R ^l   de Pril, V ^l   Hoos, A ^l   Wolchok, J D ^m  

^a Angeles Clinic and Research Institute   (United States)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY OF CHICAGO   (United States)

^e Universitatsklinik fur Dermatologie   (Austria)

^f Dnipropetrovsk State Medical Academy   (Ukraine)

^g UNIVERSITY OF GENOA   (Italy)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ Regional Clinical Oncology Dispensary   (Russian Federation)

^j Leningrad Regional Oncology Center   (Russian Federation)

^k UNIVERSITY OF NEW MEXICO   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Cytotoxic T lymphocyte antigen 4; Immunotherapy; Ipilimumab; Metastatic melanoma; Phase II clinical trial

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB;

ACUTE GLOMERULONEPHRITIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOVOLEMIC SHOCK; IMMUNOPATHOLOGY; LIVER DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TEMPORAL ARTERITIS;

EID: 77955256254     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq013     Document Type: Article

References (32)

1. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9: 587-595.
2. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27: 2823-2830.
3. Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
4. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627.
5. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
6. Kwon ED, Hurwitz AA, Foster BA et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997; 94: 8099-8103.
7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
8. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
9. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyteassociated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100: 4712-4717.
10. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
11. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016.
12. Maker AV, Yang JC, Sherry RM et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29: 455-463.
13. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
14. Hersh EM, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J Clin Oncol 2008; 26(15s): (Abstr 9022).
15. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
16. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830.
17. Berman D, Parker SM, Chasalow SD et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. J Clin Oncol 2008; 26(15s): (Abstr 3022).
18. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
19. Wolchok J, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated, advanced melanoma: a randomized, double-blind, multicenter, phase II dose-ranging study. Lancet Oncol 2010; 11: 155-164.
20. ClinicalTrials.gov. A companion study for patients enrolled in prior/parent ipilimumab studies http://clinicaltrials.gov/show/NCT00162123 (9 October 2009, date last accessed).
21. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
22. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
23. Bedikian AY, Johnson MM, Warneke CL et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26: 624-633.
24. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 5275-5234.
25. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008; 26(15s): (Abstr LBA9011).
26. van Buren N, Bonnet MC, Dréno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23: 9008-9021.
27. Kruit WHJ, van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596-604.
28. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebocontrolled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
29. Weber JS. Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
30. Chin K, Ibrahim R, Berman D et al. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy. Ann Oncol 2008; 19 (Suppl 8): (Abstr 787P).
31. Hamid O, Chasalow SD, Tsuchihashi Z et al. Baseline and on-study tumor biopsy markers are associated with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009; 27(15s): (Abstr 9008).
32. Ku GY, Yuan J, Page DB et al. Single institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after two doses correlates with survival. Cancer 2010; in press.